2021-09-19Zeitschriftenartikel
Therapeutic Efficacy of Human Monoclonal Antibodies against Andes Virus Infection in Syrian Hamsters
dc.contributor.author | Williamson, Brandi N. | |
dc.contributor.author | Prescott, Joseph | |
dc.contributor.author | Garrido, Jose L. | |
dc.contributor.author | Alvarez, Raymond A. | |
dc.contributor.author | Feldmann, Heinz | |
dc.contributor.author | Barría, Maria I. | |
dc.date.accessioned | 2024-07-25T16:35:41Z | |
dc.date.available | 2024-07-25T16:35:41Z | |
dc.date.issued | 2021-09-19 | none |
dc.identifier.other | 10.3201/eid2710.210735 | |
dc.identifier.uri | http://edoc.rki.de/176904/11855 | |
dc.description.abstract | Andes virus, an orthohantavirus endemic to South America, causes severe hantavirus cardiopulmonary syndrome associated with human-to-human transmission. No approved treatments or vaccines against this virus are available. We show that a combined treatment with 2 monoclonal antibodies protected Syrian hamsters when administered at midstage or late-stage disease. | eng |
dc.language.iso | eng | none |
dc.publisher | Robert Koch-Institut | |
dc.subject.ddc | 610 Medizin und Gesundheit | none |
dc.title | Therapeutic Efficacy of Human Monoclonal Antibodies against Andes Virus Infection in Syrian Hamsters | none |
dc.type | article | |
dc.identifier.urn | urn:nbn:de:0257-176904/11855-2 | |
dc.type.version | publishedVersion | none |
local.edoc.container-title | Emerging Infectious Diseases | none |
local.edoc.container-issn | 1080-6059 | none |
local.edoc.pages | 4 | none |
local.edoc.type-name | Zeitschriftenartikel | |
local.edoc.container-type | periodical | |
local.edoc.container-type-name | Zeitschrift | |
local.edoc.container-url | https://wwwnc.cdc.gov/eid/ | none |
local.edoc.container-publisher-name | Centers for Disease Control and Prevention | none |
local.edoc.container-volume | 27 | none |
local.edoc.container-issue | 10 | none |
local.edoc.container-reportyear | 2021 | none |
dc.description.version | Peer Reviewed | none |